My career goals are focused on conducting clinical research in Haiti to improve access and quality of care for persons living with HIV (PWH). I have a clear passion, dedication, and perspective for improving the health of impoverished communities in Haiti. I focus on the management of both infectious and non-communicable diseases in PWH. I am the Site Coordinator for the GHESKIO Clinical Trials Unit of the AIDS Clinical Trials Group (ACTG), and I am also the Vice Chair of two ACTG randomized trials. A5362 is a clinical trial evaluating a novel drug-susceptible TB treatment shortening regimen, and ACTG 5373 is a clinical trial evaluating a novel regimen for the treatment of isoniazid-resistant TB. I am also the co-PI of a Gilead funded study to compare the efficacy of continuing a protease-inhibitor-based regimen vs. switching to bictegravir/tenofovir alafenamide/emtricitabine in patients with viral suppression on second-line antiretroviral therapy. The primary outcome is ongoing viral suppression, and the secondary outcomes include weight gain and metabolic abnormalities. I have been focused on the management of non-communicable diseases in PWH for many years. I was the lead author on an analysis of the prevalence of risk factors for cardiovascular disease among a cohort of 910 adults who initiated ART between 2002 and 2004. At the time of our analysis, median follow-up time was about 12 years, and 74% of patients had at least one risk factor, including HTN in 58%, diabetes in 8%, hypercholesteremia in 43%, obesity in 10%, and smoking in 8%. I am also leading an analysis of weight gain among over 10,000 patients who have been treated with the dolutegravir, tenofovir disoproxil fumarate, lamivudine (TLD) regimen at GHESKIO for up to 3 years. We are assessing the incidence, severity, and predictors of weight gain on TLD in this cohort. In an earlier analysis (median follow-up time 6 months) we found that 24% of ART-naïve patients initiating TLD at GHESKIO gained at least 10% body weight. Ongoing projects that I would like to highlight include:1-NIH/NIAID – ACTG 5373Koenig, Furin (Chairs); Pierre, (Vice-Chair)01/01/21 – 12/31/25A Phase III, Randomized Controlled Trial for the Treatment of Isoniazid Mono-Resistant Tuberculosis: The FIRST Study (ACTG 5373)NIH/NIAID – ACTG 53622-Metcalf (Chair); Pierre, Scarsi (Vice Chairs)Clofazimine- and Rifapentine-Containing Treatment Shortening Regimens in Drug-Susceptible Tuberculosis: The CLO-FAST Study